Gordon McCullough has been promoted to chief operating officer, field operations, of the American Heart Association (AHA; Dallas, Texas). He will be responsible for all field revenue, including the association's corporate relations program and planned giving efforts. McCullough joined the AHA in 1976 as a field representative with the Missouri affiliate and moved to that affiliate's headquarters as a development and program associate in 1978. He moved to the national center in 1983 and has held a variety of positions, serving since 1998 as executive vice president of field operations and development.

CardioGenesis (Foothill Ranch, California) promoted Darrell Eckstein from vice president of operations to interim chief financial officer, secretary and treasurer, replacing J. Stephen Wilkins, who has resigned to pursue other interests. And Michael Tuckerman was promoted from general manager, central area, to vice president, U.S. sales, replacing Thomas Kinder, who left the firm.

Richard Schwarz Jr., PhD, has been named executive director, congestive heart failure program, for Cardiome Pharma (Vancouver, British Columbia). Schwarz served previously as executive director, cardiovascular therapeutics, at Quintiles. Cardiome is a cardiac drug discovery and development company.

EP MedSystems (Mt. Arlington, New Jersey) named Dr. Praveen Dala-Krishna project engineer and Kenneth Bagnell director of operations. Dala-Krishna has served as senior consultant for Digitek Systems since 1998. From 1998 until 2001, Bagnell served as executive vice president and GM for Cramer, a maker of electro-mechanical devices for the process equipment industry. EP MedSystems makes cardiac electrophysiology products used to diagnose and treat certain disorders of cardiac rhythm.

Kenneth Sumner, PhD, has been named vice president, regulatory/clinical affairs and quality assurance at Micro Therapeutics (MTI; Irvine, California). Previously, Sumner was vice president of clinical and regulatory affairs for ATI Medical. MTI makes minimally invasive medical devices for the diagnosis and treatment of vascular disease, its flagship product being Onyx, a liquid embolic material used in the treatment of conditions that can lead to stroke.

Donald Webber has been promoted from vice president of manufacturing to chief operating officer for Novoste (Norcross, Georgia). Novoste is the developer of the Beta Cath system for brachytherapy.

Daryl Edmiston has been promoted from director of research and development to vice president of R&D of Rubicon Medical (Salt Lake City, Utah), a maker of interventional vascular devices/products.